Potential of ileal bile acid transporter inhibition as a therapeutic target in Alagille syndrome and progressive familial intrahepatic cholestasis

Alagille Syndrome ◽

Bile Acid Transporter ◽

PMU62 Improved Quality of Life in Children With Progressive Familial Intrahepatic Cholestasis Following 24 Weeks of Treatment With Odevixibat, an Ileal Bile Acid Transporter Inhibitor: Results From the Phase 3 PEDFIC 1 Study

Value in Health ◽

10.1016/j.jval.2021.04.774 ◽

2021 ◽

Vol 24 ◽

pp. S155

Author(s):

R.J. Thompson ◽

L. Kjems ◽

W. Hardikar ◽

E. Lainka ◽

P.L. Calvo ◽

...

Keyword(s):

Quality Of Life ◽

Bile Acid ◽

Phase 3 ◽

Bile Acid Transporter ◽

LBO-08-Growth analysis in children with progressive familial intrahepatic cholestasis treated with the apical sodium-dependent bile acid transporter inhibitor maralixibat

Journal of Hepatology ◽

10.1016/s0618-8278(19)30232-4 ◽

2019 ◽

Vol 70 (1) ◽

pp. e131-e132 ◽

Cited By ~ 1

Author(s):

Richard Thompson ◽

Deirdre Kelly ◽

Sanjay Rajwal ◽

Alexander Miethke ◽

Nisreen Soufi ◽

...

Keyword(s):

Bile Acid ◽

Growth Analysis ◽

Sodium Dependent ◽

Bile Acid Transporter ◽

Apical sodium-dependent bile acid transporter inhibition in children with Alagille syndrome

The Lancet ◽

10.1016/s0140-6736(21)01447-1 ◽

2021 ◽

Vol 398 (10311) ◽

pp. 1544-1545

Author(s):

Alyssa Kriegermeier ◽

Sarah Taylor

Keyword(s):

Bile Acid ◽

Alagille Syndrome ◽

Sodium Dependent ◽

Bile Acid Transporter ◽

LO4 : A phase 2, randomized, placebo-controlled study (IMAGO) of LUM001, a novel inhibitor of the apical sodium-dependent bile acid transporter (ASBT), in paediatric patients with alagille syndrome (ALGS)

Journal of Hepatology ◽

10.1016/s0168-8278(15)30150-1 ◽

2015 ◽

Vol 62 ◽

pp. S259 ◽

Cited By ~ 2

Author(s):

A. Baker ◽

D. Kelly ◽

P. McClean ◽

P. Karthikeyan ◽

P. McKiernan ◽

...

Keyword(s):

Bile Acid ◽

Alagille Syndrome ◽

Controlled Study ◽

Phase 2 ◽

Paediatric Patients ◽

Sodium Dependent ◽

Bile Acid Transporter ◽

Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders

Hepatology International ◽

10.1007/s12072-020-10070-w ◽

2020 ◽

Vol 14 (5) ◽

pp. 677-689

Author(s):

Saul J. Karpen ◽

Deirdre Kelly ◽

Cara Mack ◽

Philip Stein

Keyword(s):

Bile Acid ◽

Biliary Atresia ◽

Therapeutic Target ◽

Bile Acid Transporter ◽

Bile acid stimulation of small bile duct proliferation requires de novo expression of the apical bile acid transporter (ABAT)

Gastroenterology ◽

10.1016/s0016-5085(01)80006-8 ◽

2001 ◽

Vol 120 (5) ◽

pp. A1-A1

Author(s):

G ALPINI ◽

S GLASER ◽

J PHINIZY ◽

N KANNO ◽

H FRANCIS ◽

...

Keyword(s):

Bile Acid ◽

Bile Duct ◽

De Novo ◽

Bile Duct Proliferation ◽

Bile Acid Transporter ◽

Small Bile Duct ◽

Acid Transporter ◽

Stimulation Of

Faculty Opinions recommendation of A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13356066.793516744 ◽

2016 ◽

Author(s):

Robin Spiller

Keyword(s):

Bile Acid ◽

Idiopathic Constipation ◽

Chronic Idiopathic Constipation ◽

Bile Acid Transporter ◽

Faculty Opinions recommendation of Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13408013.14778122 ◽

2011 ◽

Author(s):

Julian Walters

Keyword(s):

Bile Acid ◽

Functional Constipation ◽

Colonic Transit ◽

Bile Acid Transporter ◽

Faculty Opinions recommendation of Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726155622.793515325 ◽

2016 ◽

Author(s):

Bruno Stieger

Keyword(s):

Bile Acid ◽

Acid Receptor ◽

Bile Acid Receptor

Faculty Opinions recommendation of Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726155622.793514873 ◽

2016 ◽

Author(s):

Meenakshisundaram Ananthanarayanan

Keyword(s):

Bile Acid ◽

Acid Receptor ◽

Bile Acid Receptor